160809-38-1

Basic information

• Product Name: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE
• Synonyms: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE;Ethyl 1-Cbz-piperidine-4-carboxylate;1,4-Piperidinedicarboxylic acid, 4-ethyl 1-(phenylMethyl) ester
• CAS NO: 160809-38-1
• Molecular Formula: C₁₆H₂₁NO₄
• Molecular Weight: 291.35
• Mol File: 160809-38-1.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 403.712°C at 760 mmHg
• Flash Point: 197.958°C
• Appearance: /
• Density: 1.166g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: 2-8°C
• PKA: -2.28±0.40(Predicted)
• CAS DataBase Reference: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE(160809-38-1)
• EPA Substance Registry System: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE(160809-38-1)

Safety Data

• Hazardous Substances Data: 160809-38-1(Hazardous Substances Data)

Usage

General Description

1-Benzyl 4-ethyl piperidine-1,4-dicarboxylate is a chemical compound with potential application in pharmaceuticals. It belongs to the class of piperidine compounds, which are known for their diverse biological activities. This specific compound is a derivative of piperidine-1,4-dicarboxylate, which can potentially act as an inhibitor for certain enzymes or receptors, making it useful in drug development. Its structural features make it a promising candidate for further research and development in the field of medicinal chemistry.

InChI:InChI=1/C16H21NO4/c1-2-20-15(18)14-8-10-17(11-9-14)16(19)21-12-13-6-4-3-5-7-13/h3-7,14H,2,8-12H2,1H3

Upstream product

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 75-03-6 ethyl iodide 
• 1126-09-6 4-carbethoxypiperidine 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 122860-33-7 benzyl 4-(hydroxymethyl)piperidine-N-carboxylate 
• 757239-38-6 4-[2-(tert-butyldimethylsilyloxy)-1-hydroxyethyl]-piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-ethyl ester 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 757239-70-6 benzyl 4-(acetyloxy)-3,3-dimethyl-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate 
• 203521-95-3 1-benzyl 4-ethyl 4-methylpiperidine-1,4-dicarboxylate 
• 1209468-79-0 benzyl 4-(bis(4-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate 
• 1209468-75-6 benzyl 4-(hydroxybis(3-methoxyphenyl)methyl)piperidine-1-carboxylate 
• 1209468-80-3 benzyl 4-(hydroxydinaphthalen-2-ylmethyl)piperidine-1-carboxylate 
• 1209468-77-8 benzyl 4-(bis(3,4-dimethoxyphenyl)(hydroxy)methyl)piperidine-1-carboxylate 
• 1209468-78-9 benzyl 4-(bis(4-(dimethylamino)phenyl)(hydroxy)methyl)piperidine-1-carboxylate 
• 161609-80-9 benzyl 4-(hydrazinylcarbonyl)piperidine-1-carboxylate 
• 21327-67-3 Ethyl(benyzloxycarbonyl)-4-allyl-isonipecotat 
• 148148-48-5 4-(N-methoxy-N-methyl-carbamoyl)-piperidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).

Caspase inhibitor and pharmaceutical composition, application and treatment method thereof

The invention provides a compound serving as a caspase inhibitor and particularly relates to a novel compound with caspase inhibition activity or a pharmaceutically acceptable salt of the novel compound, a preparation method of the novel compound and a ph

Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)

The key hydrolytic enzymes of the endocannabinoid system, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), are potential targets for various therapeutic applications. In this paper, we present more extensively the results of our previous work on piperazine and piperidine carboxamides and carbamates as FAAH and MAGL inhibitors. The best compounds of these series function as potent and selective MAGL/FAAH inhibitors or as dual FAAH/MAGL inhibitors at nanomolar concentrations. This study revealed that MAGL inhibitors should comprise leaving-groups with a conjugate acid pKa of 8-10, while diverse leaving groups are tolerated for FAAH inhibitors.